Literature DB >> 31000490

Antimicrobial consumption and bacterial resistance pattern in patients admitted in I.C.U at a tertiary care center.

Sonal Saxena1, Megha Priyadarshi2, Arpita Saxena3, Ranju Singh4.   

Abstract

BACKGROUND: Throughout the world multi drug resistant nosocomial infections are one of the leading causes of death and morbidity among hospitalized patients. Antimicrobial resistance [AMR] has become a major problem in treatment of such infections. High consumption of antimicrobials particularly in ICUs is often described as the most important factor leading to AMR.
OBJECTIVE: The aim of the study was to study the magnitude of antimicrobial resistance amongst nosocomial pathogens and the antimicrobial prescription patterns of patients admitted in intensive care unit.
METHODS: The study was conducted in I.C.U of a tertiary care government hospital in Delhi over a period of 4 months, on 100 patients admitted in I.C.U. Depending on clinical suspicion laboratory samples were collected and subjected to antimicrobial sensitivity testing. Antimicrobial prescription of these patients were collected from I.C.U records and analyzed. OBSERVATIONS: Staphylococcus aureus and Klebsiella species were the most common organism [23%]. Among patients where causative organism was isolated, two or more organisms were isolated from 50% of the samples. Most of the Klebsiella species and Acinetobacter species were resistant to beta lactam group of antibiotics such as cephalosporins and piperacillin-tazobactam. 60% of isolates of S. aureus were found to be MRSA while none of the S. aureus were resistant to linezolid and vancomycin. All patients were prescribed two or more antimicrobials while 66% patients were prescribed 3-5 antimicrobials. Commonest combination was beta lactam with metronidazole followed by levofloxacin with metronidazole with addition of aminoglycosides or linezolid as third drug. Total 20 antimicrobial agents were used in the treatment of the patients. Among these consumption [in DDD/100bed days] of metronidazole was highest [100.9] followed by fluconazole [76.6] and levofloxacin [62.7].
CONCLUSION: High usage of antimicrobial consumption has been noted in this study, prompting institution of measures to formulate and adherence to antimicrobial policy strictly.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Antimicrobial consumption; Antimicrobial resistance; DDD/100bed days; DDD{defined daily dosage of antimicrobials}; I.C.U

Year:  2019        PMID: 31000490     DOI: 10.1016/j.jiph.2019.03.014

Source DB:  PubMed          Journal:  J Infect Public Health        ISSN: 1876-0341            Impact factor:   3.718


  5 in total

1.  The Impact of an Antibiotic Stewardship Program on the Consumption of Specific Antimicrobials and Their Cost Burden: A Hospital-wide Intervention.

Authors:  Dena Firouzabadi; Ali Akbari; Laleh Mahmoudi; Alireza Sepasian
Journal:  Risk Manag Healthc Policy       Date:  2020-09-23

2.  Surveillance study of bloodstream infections, antimicrobial use, and resistance patterns among intensive care unit patients: A retrospective cross-sectional study.

Authors:  Mera A Ababneh; Mohammad Al Domi; Abeer M Rababa'h
Journal:  Int J Crit Illn Inj Sci       Date:  2022-06-24

3.  Prescription of Levofloxacin and Moxifloxacin in Select Hospitals in Uganda: A Pilot Study to Assess Guideline Concordance.

Authors:  Victoria Nambasa; Helen B Ndagije; Allan Serwanga; Leonard Manirakiza; Joanitah Atuhaire; Diana Nakitto; Ronald Kiguba; Albert Figueras
Journal:  Antibiotics (Basel)       Date:  2020-07-23

4.  Antimicrobial use and mortality among intensive care unit patients with bloodstream infections: implications for stewardship programs.

Authors:  Mera A Ababneh; Mohammad Al Domi; Abeer M Rababa'h
Journal:  Heliyon       Date:  2022-08-04

5.  Antibiotic treatment with one single dose of gentamicin at admittance in addition to a β-lactam antibiotic in the treatment of community-acquired bloodstream infection with sepsis.

Authors:  Karolina Liljedahl Prytz; Mårten Prag; Hans Fredlund; Anders Magnuson; Martin Sundqvist; Jan Källman
Journal:  PLoS One       Date:  2020-07-30       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.